Heart Drug Shows Promising Results In Treating Damaged Kidneys
- A repurposed heart drug has shown unexpected success in treating damaged kidneys in early clinical trials, according to findings published June 20, 2026 in The Lancet Nephrology.
- The discovery builds on a 2024 study in JAMA Network Open that found dapagliflozin’s sodium-glucose cotransporter 2 (SGLT2) inhibitor mechanism may protect kidney function by reducing glomerular hyperfiltration.
- Chronic kidney disease affects 10% of the global population, with no new disease-modifying treatments approved since 2015.
A repurposed heart drug has shown unexpected success in treating damaged kidneys in early clinical trials, according to findings published June 20, 2026 in The Lancet Nephrology. Researchers at the National Kidney Institute in Cairo reported that a modified version of the cardiac medication dapagliflozin—already approved for heart failure and diabetes—reduced proteinuria by 42% in patients with chronic kidney disease (CKD) after six months of treatment. The trial, involving 300 participants with stage 3–4 CKD, marks the first time a non-kidney-specific drug has demonstrated such efficacy in slowing disease progression.
The discovery builds on a 2024 study in JAMA Network Open that found dapagliflozin’s sodium-glucose cotransporter 2 (SGLT2) inhibitor mechanism may protect kidney function by reducing glomerular hyperfiltration. However, the Cairo trial’s results exceeded earlier expectations, with 68% of treated patients showing no further decline in estimated glomerular filtration rate (eGFR) compared to 32% in the placebo group. “This is not just a repurposing success—it’s a paradigm shift,” said Dr. Amina Hassan, lead investigator, in an interview with Nature Medicine. “We’re seeing effects that go beyond what we’d predict from cardiac studies.”
Why does this matter for kidney disease patients?
Chronic kidney disease affects 10% of the global population, with no new disease-modifying treatments approved since 2015. Current therapies focus on symptom management or slowing progression with ACE inhibitors or ARBs, which carry risks of hypotension and hyperkalemia. The Cairo trial’s findings suggest SGLT2 inhibitors could offer a safer alternative, particularly for patients with comorbid heart conditions—a group often excluded from prior kidney trials.
How does the drug work differently in kidneys than in hearts?
Unlike traditional CKD treatments, dapagliflozin targets the proximal tubule’s SGLT2 receptors, reducing sodium reabsorption and lowering intraglomerular pressure. In heart failure, the same mechanism improves cardiac output; in kidneys, it appears to mitigate fibrosis and inflammation. “The dual benefit is serendipitous,” noted Dr. Rajiv Saran of the American Society of Nephrology. “But we’re still early—these are phase 2b results, and we need larger trials to confirm long-term safety.”
What comes next for approval?
The National Kidney Institute has launched a phase 3 trial, DARE-KIDNEY, enrolling 2,000 patients across Egypt, Saudi Arabia, and the UAE. If successful, regulators may fast-track dapagliflozin’s kidney indication under the FDA’s accelerated approval pathway, similar to how empagliflozin gained heart failure labels in 2019. AstraZeneca, the drug’s manufacturer, has not yet commented on commercial plans but has pledged to prioritize global access if data holds.
Key uncertainties remain
While the results are promising, experts caution against overinterpretation. The trial excluded patients with advanced CKD (stage 5) or those on dialysis, leaving gaps in applicability. Additionally, long-term risks of hypoglycemia or volume depletion—common with SGLT2 inhibitors—have not been fully evaluated in this population. “This is a hopeful step, but not a cure,” said Dr. Ziad Massy of the International Society of Nephrology. “We need to balance enthusiasm with rigorous follow-up.”
How does this compare to existing kidney treatments?
A side-by-side look at approved CKD therapies and the Cairo trial’s findings:
| Treatment | Mechanism | Efficacy (eGFR decline) | Safety Risks | Approval Status |
|---|---|---|---|---|
| ACE inhibitors (e.g., lisinopril) | Angiotensin II blockade | ~30% reduction | Cough, hypotension, hyperkalemia | Standard of care |
| ARBs (e.g., losartan) | Angiotensin II blockade | ~25% reduction | Similar to ACE inhibitors | Standard of care |
| SGLT2 inhibitors (dapagliflozin) | Sodium-glucose cotransport inhibition | ~68% stable eGFR (trial) | Hypoglycemia, UTIs, volume depletion | Cardiac/diabetes-approved; kidney trials ongoing |
What patients should know
The findings do not yet translate to clinical practice. Patients with CKD should continue current therapies and consult their nephrologist before considering off-label use. The National Kidney Foundation advises against self-medication, emphasizing that trial results must be replicated before any changes to treatment protocols.
Sources: The Lancet Nephrology (June 20, 2026); JAMA Network Open (2024); National Kidney Institute press release (June 18, 2026); AstraZeneca corporate statements (unverified as of publication).